Impacting Cancer

Nextech Invest, February 2017
Is this email not displaying correctly?
View it in your browser.

Dear Reader, 

We congratulate William G. Kaelin, Jr., M.D., Professor at Dana-Farber Cancer Institute and member of the Nextech Scientific Board, on winning the Lasker Basic Medical Research Award. In an exclusive interview Professor Kaelin and John A. Josey, Chief Executive Officer of Peloton Therapeutics, share their insight on how Dr. Kaelin's discovery can help patients with kidney cancer. We further welcome Neon Therapeutics to our portfolio and highlight extraordinary Proof-of-Concept data from several Phase I clinical trials by Blueprint Medicines. In the Nextech Insights, Thilo Schroeder reviews value creation in cancer drug development.

With kind regards, 
The Nextech Team



William Kaelin and John Josey show how oxygen sensing helps kidney cancer patients

Dr. William G. Kaelin, Professor at Dana-Farber Cancer Institute, received the prestigious Lasker Award for his groundbreaking research on HIF (Hypoxia-Inducible Factor), a key target in renal cancer. In our interview Dr. Kaelin and Dr. Josey, CEO of Peloton Therapeutics, talk about the history and relevance of the cancer drug target HIF and Peloton's effort to develop a drug against renal cancer. 

Read the interview

Portfolio News

Nextech Invest welcomes Neon Therapeutics to the portfolio

Neon Therapeutics closed a USD 70 million Series B financing round. The financing was lead by Partner Fund Management joined by Nextech Invest, additional new investors included Fidelity Management & Research Company, Wellington Management Company, Inbio Ventures, as well as existing investors Third Rock Ventures and Access Industries. Neon Therapeutics is an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer. Proceeds from the financing will be used to advance Neon Therapeutics’ lead program NEO-PV-01, a fully personalized neoantigen vaccine, through an ongoing Phase Ib clinical trial.

Read the press release

Nextech Insights

Value creation in cancer drug development 


In this edition of Nextech Insights, Thilo Schroeder, Partner at Nextech Invest and head of the investment team, presents an analysis of the underlying mechanisms of value creation in oncology.

Read the article.


Blueprint Medicinces (NASDAQ:BPMC) announced Proof-of-Concept for two novel cancer drug candidates, BLU-285 and BLU-554.

Read the press releases on BLU-285 in gastrointestinal stromal tumors, BLU-285 in systemic mastocytosis and BLU-554 in hepatocellular carcinoma.


Dr. William G. Kaelin received 2016 Albert Lasker Basic Medical Research Award together with Drs. Peter J. Ratcliffe and Gregg L. Semenza for their groundbreaking work on oxygen sensing.

Read the details here.

Jounce Therapeutics completed a USD 104 million IPO on NASDAQ selling 6.37 million shares at USD 16 per share. The offering closed above the inital target of USD 75 millionand indicated range of USD 13-15 per share.

Read the press release.

Kura Oncology (NASDAQ:KURA) presented preclinical data on KO-947 and menin-mixed lineage leukaemia (MLL) inhibitor program at the EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics.

Read the press release

Nextech Invest Ltd.
Bahnhofstrasse 18
8001 Zurich, Switzerland